Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/41250
metadata.artigo.dc.title: Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review
metadata.artigo.dc.creator: Hashem, Anwar M.
Alghamdi, Badrah S.
Algaissi, Abdullah A.
Alshehri, Fahad S.
Bukhari, Abdullah
Alfaleh, Mohamed A.
Memish, Ziad A.
metadata.artigo.dc.subject: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19
Chloroquine
Hydroxychloroquine
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: 2020
metadata.artigo.dc.identifier.citation: HASHEM, A. M. et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review. Travel Medicine and Infectious Disease, [S.l.], 2020. No prelo.
metadata.artigo.dc.description.abstract: The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S1477893920302143
http://repositorio.ufla.br/jspui/handle/1/41250
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.